Peringatan Keamanan

Data regarding overdoses and LD50 are not readily available.

Polatuzumab vedotin

DB12240

biotech approved investigational

Deskripsi

Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.L6658 The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab.L6658

Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 A254936 and was approved by Health Canada on July 9, 2020.L44141

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal half-life of polatuzumab vedotin is approximately 12 days (95% CI: 8.1 to 19.5 days) at Cycle 6. The terminal half-life of unconjugated MMAE is approximately four days after the first dose of polatuzumab vedotin.[L6658]
Volume Distribusi The estimated central volume of distribution of polatuzumab vedotin based on population PK analysis is 3.15 L.[L6658]
Klirens (Clearance) The predicted clearance of polatuzumab vedotin is 0.9 L/day.[L6658]

Absorpsi

After the first polatuzumab vedotin dose of 1.8 mg/kg, the mean (± SD) Cmax of antibody-conjugated MMAE and unconjugated MMAE were 803 (± 233) ng/mL and 6.82 (± 4.73) ng/mL, respectively.L6658 The mean AUCinf of antibody-conjugated MMAE and unconjugated MMAE were 1860 (± 966) day x ng/mL and 52.3 (± 18.0) day x ng/mL, respectively.L6658

Metabolisme

Polatuzumab vedotin is expected to undergo catabolism into small peptides, amino acids, unconjugated MMAE, and unconjugated MMAE-related catabolites. MMAE is metabolized by CYP3A4/5.L44141

Rute Eliminasi

Polatuzumab vedotin is predominantly excreted in feces, as well as in urine to some extent.A20351,L44141

Interaksi Makanan

1 Data
  • 1. Exercise caution with grapefruit products. The active ingredient of polatuzumab vedotin, monomethyl auristatin E (MMAE), is a CYP3A4 substrate and grapefruit may increase MMAE plasma concentrations.

Interaksi Obat

518 Data
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Polatuzumab vedotin.
Estrone Estrone may increase the thrombogenic activities of Polatuzumab vedotin.
Dienestrol Dienestrol may increase the thrombogenic activities of Polatuzumab vedotin.
Estriol Estriol may increase the thrombogenic activities of Polatuzumab vedotin.
Quinestrol Quinestrol may increase the thrombogenic activities of Polatuzumab vedotin.
Hexestrol Hexestrol may increase the thrombogenic activities of Polatuzumab vedotin.
Tibolone Tibolone may increase the thrombogenic activities of Polatuzumab vedotin.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Polatuzumab vedotin.
Zeranol Zeranol may increase the thrombogenic activities of Polatuzumab vedotin.
Equol Equol may increase the thrombogenic activities of Polatuzumab vedotin.
Promestriene Promestriene may increase the thrombogenic activities of Polatuzumab vedotin.
Methallenestril Methallenestril may increase the thrombogenic activities of Polatuzumab vedotin.
Epimestrol Epimestrol may increase the thrombogenic activities of Polatuzumab vedotin.
Moxestrol Moxestrol may increase the thrombogenic activities of Polatuzumab vedotin.
Biochanin A Biochanin A may increase the thrombogenic activities of Polatuzumab vedotin.
Formononetin Formononetin may increase the thrombogenic activities of Polatuzumab vedotin.
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Polatuzumab vedotin.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Polatuzumab vedotin.
Estradiol Estradiol may increase the thrombogenic activities of Polatuzumab vedotin.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Polatuzumab vedotin.
Mestranol Mestranol may increase the thrombogenic activities of Polatuzumab vedotin.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Polatuzumab vedotin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Polatuzumab vedotin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Polatuzumab vedotin.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Polatuzumab vedotin.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Polatuzumab vedotin.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Polatuzumab vedotin.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Polatuzumab vedotin.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Polatuzumab vedotin.
Estetrol Estetrol may increase the thrombogenic activities of Polatuzumab vedotin.
Pitolisant The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Pitolisant.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Polatuzumab vedotin.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Polatuzumab vedotin.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Polatuzumab vedotin.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Polatuzumab vedotin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Polatuzumab vedotin.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Polatuzumab vedotin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Polatuzumab vedotin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Polatuzumab vedotin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Polatuzumab vedotin.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Polatuzumab vedotin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Polatuzumab vedotin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Polatuzumab vedotin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Polatuzumab vedotin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Polatuzumab vedotin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Polatuzumab vedotin.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Polatuzumab vedotin.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Polatuzumab vedotin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Polatuzumab vedotin.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Polatuzumab vedotin.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Polatuzumab vedotin.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Polatuzumab vedotin.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Polatuzumab vedotin.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Polatuzumab vedotin.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Polatuzumab vedotin.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Polatuzumab vedotin.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Polatuzumab vedotin.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Polatuzumab vedotin.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Polatuzumab vedotin.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Polatuzumab vedotin.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Polatuzumab vedotin.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Polatuzumab vedotin.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Polatuzumab vedotin.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Polatuzumab vedotin.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Polatuzumab vedotin.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Polatuzumab vedotin.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Polatuzumab vedotin.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Polatuzumab vedotin.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Polatuzumab vedotin.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Polatuzumab vedotin.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Polatuzumab vedotin.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Polatuzumab vedotin.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Polatuzumab vedotin.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Polatuzumab vedotin.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Polatuzumab vedotin.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Polatuzumab vedotin.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Polatuzumab vedotin.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Polatuzumab vedotin.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Polatuzumab vedotin.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Polatuzumab vedotin.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Polatuzumab vedotin.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Polatuzumab vedotin.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Polatuzumab vedotin.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Polatuzumab vedotin.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Polatuzumab vedotin.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Polatuzumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Polatuzumab vedotin.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Polatuzumab vedotin.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Polatuzumab vedotin.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Polatuzumab vedotin.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Polatuzumab vedotin.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Polatuzumab vedotin.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Polatuzumab vedotin.
Ipilimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Polatuzumab vedotin.
Nimotuzumab The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Polatuzumab vedotin.
Clenoliximab The risk or severity of adverse effects can be increased when Clenoliximab is combined with Polatuzumab vedotin.

Target Protein

B-cell antigen receptor complex-associated protein beta chain CD79B

Referensi & Sumber

Artikel (PubMed)
  • PMID: 31101489
    Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP: Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 2019 May 14. pii: S1470-2045(19)30091-9. doi: 10.1016/S1470-2045(19)30091-9.
  • PMID: 25048520
    Han TH, Zhao B: Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos. 2014 Nov;42(11):1914-20. doi: 10.1124/dmd.114.058586. Epub 2014 Jul 21.
  • PMID: 31352604
    Deeks ED: Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475. doi: 10.1007/s40265-019-01175-0.
  • PMID: 34595463
    Assi R, Masri N, Dalle IA, El-Cheikh J, Ghanem H, Bazarbachi A: Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Clin Hematol Int. 2021 Mar 13;3(1):21-26. doi: 10.2991/chi.k.210305.001. eCollection 2021 Mar.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Polivy
    Injection, powder, lyophilized, for solution • 30 mg/1.88mL • Intravenous • US • Approved
  • Polivy
    Powder, for solution • 30 mg / vial • Intravenous • Canada • Approved
  • Polivy
    Powder, for solution • 140 mg / vial • Intravenous • Canada • Approved
  • Polivy
    Injection, powder, for solution • 140 mg • Intravenous • EU • Approved
  • Polivy
    Injection, powder, for solution • 30 mg • Intravenous • EU • Approved
  • Polivy
    Injection, powder, lyophilized, for solution • 140 mg/7.52mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul